Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Operating Expenses: 2021-2025

Historic Operating Expenses for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $56.4 million.

  • Krystal Biotech's Operating Expenses fell 8.05% to $56.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.0 million, marking a year-over-year increase of 0.45%. This contributed to the annual value of $224.8 million for FY2024, which is 40.14% up from last year.
  • Latest data reveals that Krystal Biotech reported Operating Expenses of $56.4 million as of Q3 2025, which was down 0.54% from $56.7 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Operating Expenses ranged from a high of $61.7 million in Q2 2024 and a low of $14.4 million during Q1 2021.
  • For the 3-year period, Krystal Biotech's Operating Expenses averaged around $50.0 million, with its median value being $51.9 million (2024).
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 249.91% in 2022, then fell by 8.07% in 2025.
  • Krystal Biotech's Operating Expenses (Quarterly) stood at $21.9 million in 2021, then soared by 58.95% to $34.8 million in 2022, then rose by 12.18% to $39.0 million in 2023, then climbed by 27.72% to $49.8 million in 2024, then dropped by 8.05% to $56.4 million in 2025.
  • Its last three reported values are $56.4 million in Q3 2025, $56.7 million for Q2 2025, and $52.0 million during Q1 2025.